Replimune Group, Inc. (REPL): Price and Financial Metrics


Replimune Group, Inc. (REPL): $20.32

0.34 (+1.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

REPL Stock Price Chart Interactive Chart >

Price chart for REPL

REPL Price/Volume Stats

Current price $20.32 52-week high $30.89
Prev. close $19.98 52-week low $13.05
Day low $19.61 Volume 403,000
Day high $20.40 Avg. volume 306,572
50-day MA $18.46 Dividend yield N/A
200-day MA $17.73 Market Cap 1.01B

Replimune Group, Inc. (REPL) Company Bio


Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer. It is developing various proprietary products intended to enhance the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The company was founded in 2015 is based in Abingdon, the United Kingdom.


REPL Latest News Stream


Event/Time News Detail
Loading, please wait...

REPL Latest Social Stream


Loading social stream, please wait...

View Full REPL Social Stream

Latest REPL News From Around the Web

Below are the latest news stories about REPLIMUNE GROUP INC that investors may wish to consider to help them evaluate REPL as an investment opportunity.

Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, December 1, 2022 at 1:00 PM ET. About Replimune Replimune Group, Inc., headqu

Yahoo | November 23, 2022

Replimune to Host Virtual Investor Event on December 7, 2022

Event to begin at 8:00 AM ETWOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team will host an investor event to provide a data update that will include preliminary data from the six-month follow-up of the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with

Yahoo | November 22, 2022

Replimune Group (REPL) Gets a Buy from BMO Capital

BMO Capital analyst Evan Seigerman maintained a Buy rating on Replimune Group (REPL - Research Report) today and set a price target of $40.00. The company's shares opened today at $17.74.Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Regeneron, and Bristol Myers. According to TipRanks, Seigerman has an average return of 6.3% and a 53.85% success rate on recommended stocks. Currently, the analyst consensus on Replimune Group is a Strong Buy with an average price target of $38.80, which is an 118.71% upside from current levels. In a report released on November 4, H.C.

Brian Anderson on TipRanks | November 8, 2022

Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Horizon Therapeutics (HZNP – Research Report), Crispr Therapeutics AG (CRSP – Research Report) and Replimune Group (REPL – Research Report) with bullish sentiments. Horizon Therapeutics (HZNP) BMO Capital analyst Gary Nachman maintained a Buy rating on Horizon Therapeutics today and set a price target of $117.00. The company's shares closed last Thursday at $71.92. According to TipRanks.

Brian Anderson on TipRanks | November 3, 2022

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

Completed enrollment in the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1 2023 Six-month follow-up data from the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo® (nivolumab) in anti-PD1 failed melanoma expected by year end An update on the RP2/3 development program remains on track to be provided by year end Completed $200 million term-loan tha

Yahoo | November 3, 2022

Read More 'REPL' Stories Here

REPL Price Returns

1-mo 9.60%
3-mo N/A
6-mo 20.52%
1-year -26.54%
3-year 50.85%
5-year N/A
YTD -25.02%
2021 -28.96%
2020 165.85%
2019 43.50%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6046 seconds.